OncoDNA's Friendly Takeover of IntegraGen

Scientific Application Note

PROSTATE CANCER The FDA have granted accelerated approval to the PARP inhibitor rucaparib for BRCA-mutated (germline or somatic) metastatic castrate-resistant disease.

May 26th

FDA GRANTS ACCELERATED APPROVAL TO RUCAPARIB FOR BRCA-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER FDA On May 15, 2020, the Food and Drug Administration granted accelerated approval to rucaparib (RUBRACA, Clovis Oncology, Inc.) for patients with deleterious...

Scientific Application Note

COVID-19 PANDEMIC Urgent referrals for suspected cancer were down 60% in April in the UK; some cancer types were differentially affected with suspected breast cancer referrals down 78%.

Jun 22nd

These reports present the validated results of the monitoring of waiting times for cancer services in England and the information on the number of people who attended outpatient appointments within two weeks of an urgent...

Poster

Whole genome cell-free tumor DNA mutational signatures for noninvasive monitoring of pediatric brain cancers

5 min reading

Jan 8th

Overview: The technique of liquid biopsy represents a groundbreaking non-invasive method for tracking cancer progression and remission, particularly during treatment and follow-up phases. Despite its promise, the application of liquid biopsy in pediatric brain cancer...

Agreement to file a friendly takeover bid initiated by OncoDNA on IntegraGen to acquire all outstanding shares at a price of 2.20€ per share

You may also be interested in these resources

PROSTATE CANCER The FDA have granted accelerated approval to the PARP inhibitor rucaparib for BRCA-mutated (germline or somatic) metastatic castrate-resistant disease.

COVID-19 PANDEMIC Urgent referrals for suspected cancer were down 60% in April in the UK; some cancer types were differentially affected with suspected breast cancer referrals down 78%.

Whole genome cell-free tumor DNA mutational signatures for noninvasive monitoring of pediatric brain cancers